Komori
Earnings presentation4891TMS Co.,Ltd.Pharmaceuticals

(Correction) Notice Concerning Partial Correction to the "Presentation Materials on Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026"

The chart showing the progress of the clinical trial for TMS-007 (JX10) on page 9 of the financial results presentation materials released on 14 August 2026 was partially revised, and the red-outlined area in the chart was deleted.

Worth reading
16Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure14 August 2026

Financial Results Presentation for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026

Open the original document
11 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-08-25
Location of correction (where in the original document)

P9. The red-outlined area in the upper chart showing the progress of the clinical trial for TMS-007 (JX10)

ChangesDeletion of the red-outlined area in the upper chart
What was corrected and how
ItemDetails
Disclosure subject to correctionFinancial Results Presentation for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026
Original disclosure date14 August 2026
Location of correctionP9. The red-outlined area in the upper chart showing the progress of the clinical trial for TMS-007 (JX10)
Details of correctionDeletion of the red-outlined area in the upper chart
Items this document does not state (2)
Reason for correctionImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The correction is explained, but no specific reason for the correction is provided.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Notice Concerning Partial Correction to the "Presentation Materials on Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026" | TMS Co.,Ltd. (4891) timely disclosure | Komori